Alzheimer’s research seeing ‘exceptionally high levels’ of innovation
Nearly two-thirds of pipeline products have first-in-class potential
Read MoreNearly two-thirds of pipeline products have first-in-class potential
Read MoreBut consent would be key for the use of home camera-based systems
Read MoreMental health not a high enough priority for NHS vanguards, says King’s Fund
Read MoreStrikes licensing deal with Remedy Pharmaceuticals
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479